Our CRISPR‐based study highlights the therapeutic potential of targeting NKRF and ZBTB17 expressions to manage Alzheimer's disease (AD) and atherosclerosis (AS). This evidence concerns the gene ZBTB17 and early-onset autosomal dominant Alzheimer disease.